Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
Website: interpace.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 20.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +17.3%. On average the margin is improving steadily. Gross margin is high, +63.8%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.96 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -108.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 212.2% higher than minimum and 48.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 8.6x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: IDXG
Share price, USD:  (0.0%)1.75
year average price 1.0188  


year start price 1.1875 2025-02-13

min close price 0.6450 2025-05-08

max close price 1.7900 2026-01-20

current price 1.7500 2026-02-12
Common stocks: 4 229 940

Dividend Yield:  0.0%
FCF Yield LTM: -108.1%
EV / LTM EBITDA: 0.8x
EV / EBITDA annualized: 0.4x
Last revenue growth (y/y):  > +200.0%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +20.5%
Historical growth of EBITDA:  0.0%
EV / Sales: 0.1x
Margin (EBITDA LTM / Revenue): 17.3%
Fundamental value created in LTM:
Market Cap ($m): 7
Net Debt ($m): 4
EV (Enterprise Value): 11
Price to Book: -24.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-01-31globenewswire.com

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

2025-01-09globenewswire.com

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

2024-07-29globenewswire.com

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2023-11-08 2023-08-09 2023-05-12 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2025-03-31 16:01:51 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-26 16:39:36 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55 2022-04-29 18:24:05 2021-04-29 16:05:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 9M 9M 47M 12M 12M 10M 40M 9M 11M 10M 32M 8M 41M 32M
costOfRevenue 3M 4M 17M 5M 5M 4M 16M 4M 4M 4M 14M 3M 23M 22M
grossProfit 5M 5M 30M 8M 7M 6M 24M 5M 7M 6M 18M 5M 18M 11M
grossProfitRatio 0.621 0.571 0.61 0.617 0.591 0.524 0.62 0.608 0.578
researchAndDevelopmentExpenses 150 000 173 000 676 000 199 000 146 000 137 000 636 000 149 000 186 000 149 000 703 000 191 000 2M 3M
generalAndAdministrativeExpenses 2M 3M 9M 3M 2M 2M 9M 2M 3M 2M 11M 3M 14M 21M
sellingAndMarketingExpenses 2M 3M 12M 3M 3M 3M 10M 2M 3M 2M 9M 2M 10M 9M
sellingGeneralAndAdministrativeExpenses 4M 6M 21M 5M 5M 5M 20M 5M 5M 5M 20M 5M 24M 30M
otherExpenses 0 0 0 0 71 000 -82 000 868 000 0 -174 000 318 000 1M 318 000 4M 4M
operatingExpenses 4M 6M 22M 6M 5M 5M 21M 5M 6M 5M 22M 6M 30M 37M
costAndExpenses 8M 10M 39M 10M 10M 9M 37M 9M 10M 9M 36M 9M 53M 59M
interestIncome 0 0 0 0 0 0 0 256 000 259 000 0 0 0 0 0
interestExpense 0 49 000 659 000 145 000 188 000 216 000 1M 256 000 259 000 260 000 1M 268 000 1M 549 000
depreciationAndAmortization 111 000 199 000 748 000 85 000 188 000 160 000 1M 240 000 358 000 375 000 3M 418 000 5M 6M
ebitda 1M -285 000 8M 2M 2M 1M 4M 224 000 1M 1M -2M -362 000 -1M -20M
ebitdaratio 0.127 -0.031 0.13 0.203 0.101 0.025 0.092 0.107 -0.044
operatingIncome 1M -468 000 8M 2M 2M 874 000 3M -16 000 832 000 675 000 -4M -780 000 -12M -27M
operatingIncomeRatio 0.131 -0.051 0.155 0.187 0.085 -0.002 0.075 0.069 -0.095
totalOtherIncomeExpensesNet -145 000 42 000 -1M -539 000 -117 000 -298 000 -2M -508 000 -174 000 -241 000 -2M -485 000 -1M -82 000
incomeBeforeTax 1 000 000 -426 000 7M 1M 2M 576 000 1M -524 000 399 000 434 000 -6M -1M -15M -26M
incomeBeforeTaxRatio 0.114 -0.046 0.111 0.178 0.056 -0.058 0.036 0.044 -0.154
incomeTaxExpense 11 000 107 000 4000 4000 4000 4000 17 000 4000 4000 4000 29 000 -11 000 -667 000 53 000
netIncome 911 000 -640 000 7M 1M 2M 468 000 802 000 -614 000 175 000 351 000 -6M -1M -15M -26M
netIncomeRatio 0.104 -0.069 0.104 0.171 0.046 -0.068 0.016 0.036 -0.153
eps 0.23 -0.14 1.42 0.29 0.47 0.11 0.19 -0.14 0.04 0.08 -1.38 -0.3 -3.57 -6.5
epsdiluted 0.04 -0.14 0.29 0.47 0.11 -0.14 0.04 0.08 -0.3
weightedAverageShsOut 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M
weightedAverageShsOutDil 28M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-04-26 2023-03-27 2022-05-02 2021-04-29
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -659 000 -1M -1M -1M -549 000
ebit 8M 3M -5M -7M -26M
nonOperatingIncomeExcludingInterest 499 000 -7000 1M 366 000 -467 000
netIncomeFromContinuingOperations 7M 1M -6M -7M -26M
netIncomeFromDiscontinuedOperations -244 000 -310 000 0 0 0
otherAdjustmentsToNetIncome 0 0 -16M -8M -250 000
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 6M 802 000 -22M -15M -29M
epsDiluted 0.4 0.18 -1.38 -3.57 -6.5

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2023-11-08 2023-08-09 2023-05-12 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2025-03-31 16:01:51 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-26 16:39:36 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55 2022-04-29 18:24:05 2021-04-29 16:05:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1M 502 000 1M 2M 2M 3M 3M 5M 5M 6M 5M 6M 3M 3M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 1M 502 000 1M 2M 2M 3M 3M 5M 5M 6M 5M 6M 3M 3M
netReceivables 6M 7M 9M 7M 6M 5M 5M 5M 6M 5M 5M 5M 5M 8M
inventory 0 973 000 1M 0 1M 1M 1M 1M 1M 1M 1M 1M 2M 2M
otherCurrentAssets 2M 798 000 22 000 2M 710 000 444 000 24 000 43 000 48 000 172 000 680 000 138 000 3M 645 000
totalCurrentAssets 9M 10M 12M 11M 10M 9M 10M 11M 13M 12M 12M 13M 12M 14M
propertyPlantEquipmentNet 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 1M 10M 12M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 8M 8M
intangibleAssets 0 0 0 0 0 0 0 27 000 226 000 544 000 861 000 1M 7M 11M
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 27 000 226 000 544 000 861 000 1M 16M 20M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 45 000 45 000 45 000 45 000 44 999 44 999 45 000 45 000 45 000 45 000 45 000 80 000 160 000 42 000
totalNonCurrentAssets 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 4M 3M 26M 32M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 12M 12M 15M 14M 13M 12M 13M 14M 16M 16M 16M 15M 38M 46M
accountPayables 1M 1M 2M 2M 2M 1M 2M 1M 2M 2M 1M 1M 1M 5M
shortTermDebt 0 2M 4M 0 7M 8M 5M 414 000 2M 3M 3M 3M 0 0
taxPayables 0 223 000 262 000 259 000 308 000 276 000 261 000 238 000 222 000 279 000 262 000 85 000 245 000 334 000
deferredRevenue 0 0 0 0 308 000 276 000 0 10M 9M 0 0 0 40 000 54 000
otherCurrentLiabilities 5M 3M 660 000 17M 10M 9M 8M 858 000 858 000 10M 2M 10M 11M 9M
totalCurrentLiabilities 6M 7M 11M 19M 19M 19M 17M 12M 14M 14M 14M 15M 16M 18M
longTermDebt 864 000 974 000 0 1M 1M 1M 4M 13M 13M 13M 11M 10M 9M 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 13 000 136 000
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 47M 4M
otherNonCurrentLiabilities 6M 5M 5M 5M 5M 6M 5M 51M 52M 52M 52M 57M 55M 6M
totalNonCurrentLiabilities 6M 6M 6M 6M 6M 8M 11M 65M 65M 65M 65M 62M 65M 57M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 1M 2M 1M 2M 1M 2M 2M 2M 2M 2M 852 000 1M 5M
totalLiabilities 12M 14M 17M 25M 25M 27M 28M 77M 78M 78M 79M 77M 81M 75M
preferredStock 0 0 0 0 47M 47M 47M 47M 47M 47M 47M 0 47M 46M
commonStock 407 000 407 000 406 000 406 000 406 000 406 000 405 000 405 000 405 000 405 000 405 000 404 000 403 000 402 000
retainedEarnings -233M -234M -235M -244M -246M -248M -248M -249M -248M -249M -249M -247M -227M -212M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 -47M -93M 0 0 -47M -47M 0 -47M 0 0 -46M
othertotalStockholdersEquity 233M 233M 279M 372M 186M 186M 186M 139M 185M
totalStockholdersEquity -298 000 -1M -2M -11M -12M -15M -15M -63M -62M -63M -63M -62M -42M -29M
totalEquity -298 000 -1M -2M -11M -12M -15M -15M -63M -62M -63M -63M -62M -42M -29M
totalLiabilitiesAndStockholdersEquity 12M 12M 14M 13M 12M 14M 16M 16M 15M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 12M 12M 15M 14M 13M 12M 13M 14M 16M 16M 16M 15M 38M 46M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 864 000 3M 6M 1M 8M 11M 11M 14M 15M 16M 16M 13M 14M 5M
netDebt -559 000 3M 4M -924 000 6M 8M 8M 9M 10M 10M 11M 7M 10M 2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-31 2024-04-26 2023-03-27 2022-05-02 2021-04-29
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 9M 5M 5M 5M 8M
otherReceivables 0 0 0 0 0
prepaids 535 000 590 000 390 000 584 000 625 000
totalPayables 2M 2M 1M 2M 5M
otherPayables 262 000 261 000 0 222 000 334 000
accruedExpenses 3M 2M 8M 3M 3M
capitalLeaseObligationsCurrent 383 000 377 000 578 000 762 000 1M
capitalLeaseObligationsNonCurrent 1M 1M 2M 520 000 4M
treasuryStock -2M -2M -2M -2M -2M
additionalPaidInCapital 235M 188M 188M 186M 184M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2023-11-08 2023-08-09 2023-05-12 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2025-04-28 16:27:54 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-26 16:39:36 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55 2022-04-29 18:24:05 2021-04-29 16:05:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 10000 -640 000 7M 1M 2M 572 000 802 000 -528 000 175 000 351 000 -22M -14M -15M -26M
depreciationAndAmortization 111 000 199 000 748 000 189 000 188 000 160 000 2M 240 000 358 000 356 000 3M 635 000 5M 6M
deferredIncomeTax 0 0 0 0 0 0 0 -314 999 0 0 -93 000 0 38 000 37 000
stockBasedCompensation 7000 9000 291 000 86 000 53 000 79 000 630 000 152 000 157 000 192 000 1M 520 000 1M 2M
changeInWorkingCapital 0 959 000 -4M 153 000 -853 000 -808 000 -83 000 1M -499 000 218 000 -3M -3M -1M 5M
accountsReceivables 0 2M -3M 0 -1M -49 000 49 000 699 000 -814 000 317 000 -133 000 395 000 2M 2M
inventory 0 0 0 0 0 0 0 -1 0 0 0 0 0 0
accountsPayables 0 -470 000 120 000 0 163 000 -176 000 489 000 -382 000 78 000 532 000 -735 000 -1M -2M -198 000
otherWorkingCapital 0 -108 000 -330 000 153 000 184 000 -583 000 -621 000 712 000 237 000 -849 000 -2M -2M -1M 4M
otherNonCashItems -128 000 -7000 581 000 408 000 1M 563 000 839 000 527 000 220 000 16 000 14M 13M 575 000 -1M
netCashProvidedByOperatingActivities 0 520 000 5M 2M 1M -58 000 4M 1M 411 000 1M -8M -3M -9M -15M
investmentsInPropertyPlantAndEquipment 0 -201 000 -876 000 0 -197 000 -28 000 -470 000 -152 000 -111 000 -65 000 -322 000 -40 000 -354 000 -2M
acquisitionsNet 0 0 0 0 0 0 383 000 500 000 -117 000 0 7M 0 39 000 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -522 000 -225 000 0 500 000 0 0 7M
netCashUsedForInvestingActivites 0 -201 000 -522 000 -197 000 -28 000 348 000 -228 000 -65 000 7M
debtRepayment 0 -1 000 000 -2M -2M -600 000 -2M -700 000 0 0
commonStockIssued 0 0 0 0 0 0 0 0 47 000
commonStockRepurchased 0 0 0 0 0 0 -32 000 0 0 0 -108 000 0 0 -52 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 -13 000 0 0 -600 000 -2M 0 -300 000 0
netCashUsedProvidedByFinancingActivities 0 -1M -2M -2M -600 000 -2M -700 000 -300 000 47 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 1M 0 0 0 0 0
netChangeInCash 0 -694 000 -2M 94 000 -793 000 -686 000 -1M -547 000 -517 000 768 000 2M 4M -58 000 451 000
cashAtEndOfPeriod 0 502 000 1M 2M 2M 3M 3M 5M 5M 6M 5M 6M 3M 3M
cashAtBeginningOfPeriod 0 1M 3M 2M 3M 3M 5M 6M 6M 5M 3M 2M 3M 2M
operatingCashFlow 0 520 000 5M 2M 1M -58 000 4M 1M 411 000 1M -8M -3M -9M -15M
capitalExpenditure 0 -201 000 -876 000 -522 000 -197 000 -28 000 -470 000 -152 000 -111 000 -65 000 -322 000 -40 000 -354 000 -2M
freeCashFlow 0 319 000 4M 2M 1M -86 000 3M 953 000 300 000 1M -8M -3M -9M -16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-04-28 2024-04-26 2023-03-27 2022-05-02 2021-04-29
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 7M 39 000 0
netCashProvidedByInvestingActivities -876 000 -87 000 6M -315 000 -2M
netDebtIssuance -6M -3M 3M 9M -3M
longTermNetDebtIssuance 0 -3M 2M 9M -3M
shortTermNetDebtIssuance -6M 0 1 000 000 2M 0
netStockIssuance 0 -32 000 0 335 000 -52 000
netCommonStockIssuance 0 -32 000 0 335 000 382 000
commonStockIssuance 0 0 108 000 335 000 434 000
netPreferredStockIssuance 0 0 0 0 19M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -3M 0 -435 000 20M
netCashProvidedByFinancingActivities -6M -5M 3M 9M 17M
incomeTaxesPaid 274 000 270 000 251 000 424 000 0
interestPaid 0 1M 971 000 369 000 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2026-01-20 14:05 ET
Interpace Biosciences published news for 2025 q4
SEC form 8
2026-01-20 14:05 ET
Interpace Biosciences published news for 2025 q4
SEC form 8
2025-12-03 16:05 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-12-03 16:05 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-11-12 16:45 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-11-12 16:45 ET
Interpace Biosciences reported for 2025 q3
SEC form 10
2025-11-12 16:17 ET
Interpace Biosciences reported for 2025 q3
SEC form 8
2025-08-08 16:28 ET
Interpace Biosciences published news for 2025 q2
SEC form 8
2025-08-08 16:28 ET
Interpace Biosciences reported for 2025 q2
SEC form 10
2025-08-07 20:30 ET
Interpace Biosciences reported for 2025 q2
SEC form 10
2025-05-08 20:28 ET
Interpace Biosciences reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Interpace Biosciences reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Interpace Biosciences published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Interpace Biosciences reported for 2025 q1
SEC form 8
2025-04-30 23:31 ET
Interpace Biosciences published news for 2025 q1
SEC form 8
2025-04-30 23:31 ET
Interpace Biosciences published news for 2025 q1
SEC form 10
2025-03-31 16:01 ET
Interpace Biosciences published news for 2024 q4
SEC form 10
2025-03-31 00:00 ET
Interpace Biosciences published news for 2024 q4
SEC form 8
2025-01-27 21:15 ET
Interpace Biosciences published news for 2024 q4
SEC form 8
2025-01-27 21:15 ET
Interpace Biosciences published news for 2024 q4
SEC form 10
2024-11-08 16:05 ET
Interpace Biosciences reported for 2024 q3
SEC form 8
2024-11-06 16:46 ET
Interpace Biosciences published news for 2024 q3
SEC form 8
2024-11-06 16:46 ET
Interpace Biosciences published news for 2024 q3
SEC form 10
2024-08-08 00:00 ET
Interpace Biosciences published news for 2024 q2
SEC form 8
2024-08-02 16:30 ET
Interpace Biosciences published news for 2024 q2
SEC form 8
2024-08-02 16:30 ET
Interpace Biosciences reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Interpace Biosciences reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Interpace Biosciences published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Interpace Biosciences published news for 2024 q1
SEC form 10
2024-04-01 17:01 ET
Interpace Biosciences published news for 2023 q4
SEC form 10
2024-04-01 00:00 ET
Interpace Biosciences published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
Interpace Biosciences published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
Interpace Biosciences reported for 2023 q4
SEC form 8
2023-11-08 17:14 ET
Interpace Biosciences published news for 2023 q3
SEC form 10
2023-11-08 16:16 ET
Interpace Biosciences reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Interpace Biosciences published news for 2023 q3
SEC form 6
2023-08-09 15:47 ET
Interpace Biosciences published news for 2023 q2
SEC form 10
2023-08-09 13:27 ET
Interpace Biosciences reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Interpace Biosciences published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Interpace Biosciences published news for 2023 q2
SEC form 6
2023-08-01 20:59 ET
Interpace Biosciences published news for 2023 q2
SEC form 6
2023-05-12 16:34 ET
Interpace Biosciences published news for 2023 q1
SEC form 10
2023-05-12 16:23 ET
Interpace Biosciences published news for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Interpace Biosciences published news for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-04-28 16:15 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-04-24 20:56 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-03-27 16:42 ET
Interpace Biosciences published news for 2022 q4
SEC form 10
2023-03-27 16:38 ET
Interpace Biosciences reported for 2022 q4
SEC form 10
2023-03-27 00:00 ET
Interpace Biosciences reported for 2022 q4
SEC form 8
2023-03-27 00:00 ET
Interpace Biosciences reported for 2022 q4
SEC form 6
2022-11-15 16:09 ET
Interpace Biosciences published news for 2022 q3
SEC form 10
2022-11-14 16:54 ET
Interpace Biosciences reported for 2022 q3
SEC form 6
2022-11-14 16:52 ET
Interpace Biosciences published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Interpace Biosciences reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Interpace Biosciences reported for 2022 q3
SEC form 6
2022-11-04 16:33 ET
Interpace Biosciences published news for 2022 q3
SEC form 6
2022-10-04 16:18 ET
Interpace Biosciences published news for 2022 q3
SEC form 6
2022-09-20 16:36 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-09-09 16:28 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-09-07 16:46 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-08-15 17:42 ET
Interpace Biosciences published news for 2022 q2
SEC form 10
2022-08-15 16:47 ET
Interpace Biosciences reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Interpace Biosciences reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Interpace Biosciences reported for 2022 q2
SEC form 10
2022-05-16 16:31 ET
Interpace Biosciences reported for 2022 q1
SEC form 6
2022-05-16 16:28 ET
Interpace Biosciences published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Interpace Biosciences reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Interpace Biosciences reported for 2022 q1
SEC form 6
2022-05-10 16:30 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-04-29 18:24 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-04-14 16:05 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-03-31 16:37 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2022-03-31 16:35 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Interpace Biosciences published news for 2021 q4
SEC form 8
2022-03-31 00:00 ET
Interpace Biosciences published news for 2021 q4
SEC form 6
2022-01-28 19:38 ET
Interpace Biosciences published news for 2021 q4
SEC form 6
2022-01-27 16:15 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2021-11-10 16:31 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-10 16:16 ET
Interpace Biosciences published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Interpace Biosciences published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-09 21:58 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-02 21:55 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-10-18 21:48 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-10-01 17:21 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-09-27 16:29 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-31 16:48 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-20 17:29 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-20 17:27 ET
Interpace Biosciences published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
Interpace Biosciences published news for 2021 q2
SEC form 10
2021-08-10 21:48 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-10 16:52 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-06 16:27 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-06-29 17:17 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-05-11 17:06 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-05-11 17:03 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-05-11 00:00 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-04-29 16:05 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-04-05 06:30 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-04-01 06:14 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-04-01 06:02 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-02-24 20:04 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-02-17 17:00 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-02-04 16:49 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-20 08:55 ET
Interpace Biosciences published news for 2020 q4
SEC form 10
2021-01-19 21:43 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2021-01-19 17:03 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-19 16:59 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-19 16:54 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-11 16:50 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2020-12-07 21:49 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-25 08:25 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-19 16:20 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-17 16:19 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-10-23 16:01 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-10-20 08:35 ET
Interpace Biosciences published news for 2020 q3
SEC form 10
2020-10-19 17:13 ET
Interpace Biosciences published news for 2020 q2
SEC form 6
2020-10-14 09:14 ET
Interpace Biosciences published news for 2020 q3